RESEARCH TRIANGLE PARK, North Carolina, September 2nd, 2015 – Precision BioSciences, the genome editing company, today announced two key additions to the executive team – Gene Liau, Ph.D., as Senior Vice President, Gene Therapy and Bruce McCreedy, Ph.D., as Senior Vice President, Cell Therapy.
“We are excited to welcome Gene and Bruce to the Precision team,” said Matthew Kane, Chief Executive Officer of Precision BioSciences. “Their proven leadership and breadth of experience will undoubtedly prove critical to our gene and cell therapy product development programs. Together, we will work to transform our class-leading ARCUS editing platform into a highly disruptive product pipeline within oncology and genetic disease.”
Dr. Liau joins Precision from Pfizer where, as Executive Director, he led External R&D for the Rare Disease Unit and spearheaded the Pfizer Gene Therapy initiative. Prior to Pfizer, Dr. Liau led groups at Novartis and Shire working on cardiovascular/metabolic diseases, gene therapy, and rare diseases. Before entering industry, Dr. Liau was a Tenured Professor at the George Washington University Medical Center and Jerome H. Holland Laboratory at the American Red Cross. He received his Ph.D. in Biochemistry from Vanderbilt University and has authored over fifty peer-reviewed publications.
“Precision Biosciences has developed one of the most exciting and powerful genome modifying technologies I have come across in my years in the industry,” said Dr. Liau. “I am delighted to have the opportunity to help Matt and the team build a therapeutic pipeline that can utilize the full potential of this unique platform.”
Precision welcomes Dr. McCreedy from NexImmune, an immunotherapy-focused company, where he served as Chief Development Officer and Executive Vice President of Research and Development. Before joining NexImmune, Dr. McCreedy served in leadership functions at Roche, LabCorp, Triangle Pharmaceuticals (now Gilead), Metabolon, and Fulcrum Pharma. He received his Ph.D. in Microbiology and Immunology from Wake Forest University and has published his research extensively in the field of immunotherapy.
“I am thrilled to be joining the talented and experienced team at Precision BioSciences and to have the opportunity to utilize the proven capability of the ARCUS genome editing platform to create novel and powerful cellular immuno-therapies for the treatment of patients with cancer,” said Dr. McCreedy.
About Precision BioSciences
Precision BioSciences is a genome editing company dedicated to improving life. Our team seeks to solve significant problems in oncology, genetic disease, agriculture, and beyond via its ARCUS genome editing platform. ARCUS is Precision’s latest and wholly proprietary genome editing platform which now encompasses an industry leading combination of site specificity, ease of delivery, and breadth of editing capabilities.
Contact Precision Biosciences
Chelsea Lynam
+1 919-314-5512
chelsea.lynam@precisionbiosciences.com